Oligodendrocyte

Type: Keyphrase
Name: Oligodendrocyte
First reported 9 hours ago - Updated 9 hours ago - 1 reports

ERK1/2 Pathway-Mediated Differentiation of IGF-1-Transfected Spinal Cord-Derived Neural Stem Cells into Oligodendrocytes

by Bo Shi, Jianxun Ding, Yi Liu, Xinming Zhuang, Xiuli Zhuang, Xuesi Chen, Changfeng FuSpinal cord injury (SCI) is a devastating event that causes substantial morbidity and mortality, for which no fully restorative treatments are available. Stem cells ... [Published Plosone.org - 9 hours ago]
First reported 10 hours ago - Updated 10 hours ago - 1 reports

Stem cell trial for spinal cord injuries cleared by FDA

An experimental treatment using controversial embryonic stem cells to fix severe spinal cord injuries has new life under a new company.Asterias Biotherapeutics Inc. of Menlo Park received Food and Drug Administration clearance Wednesday to go forward ... [Published Business First of Buffalo - 10 hours ago]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Principal Scientist: Immunoregulation

Org Marketing StatementAll over the world, Pfizer colleagues are working together to positively impact health for everyone, everywhere. Each position at Pfizer touches and contributes to the success of our business and our world. That’s why, as one of ... [Published PharmaDiversity - Aug 27 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Hsp70 Regulates Immune Response in Experimental Autoimmune Encephalomyelitis

by M. José Mansilla, Carme Costa, Herena Eixarch, Vanja Tepavcevic, Mireia Castillo, Roland Martin, Catherine Lubetzki, Marie-Stéphane Aigrot, Xavier Montalban, Carmen EspejoHeat shock protein (Hsp)70 is one of the most important stress-inducible proteins. ... [Published Plosone.org - Aug 25 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Asterias Biotherapeutics Announces Investor Briefing Conference Call and Webcast

MENLO PARK, Calif.For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S. is 877-407-8291. For participants outside the U.S., the dial-in number is ... [Published Bio-Medicine - Aug 25 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

Stem Cell Therapies Hold Promise, But Obstacles Remain

In an article appearing online today in the journal Science, a group of researchers, including University of Rochester neurologist Steve Goldman, M.D., Ph.D., review the potential and challenges facing the scientific community as therapies involving stem ... [Published Health Canal - Aug 22 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

A Prostate Cancer Drug maybe the answer to remyelination

IRX4204, a retinoid X receptor-agonist studied for prostate cancer, also promotes differentiation of oligodendrocytes and the formation of regulatory T cells and inhibits the formation of TH 17 cells in vitro, suggesting its potential for myelin repair ... [Published Multiple Sclerosis Research - Aug 21 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Methods of generating mature oligodendrocytes

A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of ... [Published Free Patents Online - Aug 19 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Saving oligodendrocytes

Vakilzadeh G, Khodagholi F, Ghadiri T, Darvishi M, Ghaemi A, Noorbakhsh F, Gorji A, Sharifzadeh M. Protective Effect of a cAMP Analogue on Behavioral Deficits and Neuropathological Changes in Cuprizone Model of Demyelination. Mol Neurobiol. 2014 Aug. ... [Published Multiple Sclerosis Research - Aug 19 2014]
First reported Aug 10 2014 - Updated Aug 10 2014 - 1 reports

Sleep deep to boost brain function

DID you know that while you sleep, there are genes in the brain that are actually turned on? Scientists now say that these genes are vital for the repair and growth of brain cells.Scientists in the US have now established that adequate sleep boosts the ... [Published Oman Observer - Aug 10 2014]
First reported Aug 03 2014 - Updated Aug 04 2014 - 3 reports

Kadimastem to Collaborate with Merck Serono to Advance Combined Efforts in Neurodegenerative Disease Area

NESS ZIONA, Israel--(BUSINESS WIRE)-- Israeli biotechnology company Kadimastem (TASE:KDST) reports that it has signed a collaboration agreement with Merck to carry out drug screening in the neurodegenerative diseases space for multiple sclerosis (MS), ... [Published Nasdaq - Aug 04 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

Oligodendrocyte Precursor Cells Support Blood-Brain Barrier Integrity via TGF-β Signaling

by Ji Hae Seo, Takakuni Maki, Mitsuyo Maeda, Nobukazu Miyamoto, Anna C. Liang, Kazuhide Hayakawa, Loc-Duyen D. Pham, Fumihiko Suwa, Akihiko Taguchi, Tomohiro Matsuyama, Masafumi Ihara, Kyu-Won Kim, Eng H. Lo, Ken AraiTrophic coupling between cerebral ... [Published Plosone.org - Jul 31 2014]

Quotes

...Timothy Coetzee , Chief Advocacy, Services and Research Officer at the National MS Society . "Repairing myelin may be the best way to protect the nervous system from MS damage, and it holds potential for restoring function that has been lost in people living with this disease" he added
...the scientists, clinical investigators, and FDA for working with us to develop AST-OPC1," stated Pedro Lichtinger, President and CEO of Asterias. "We are especially enthusiastic about working with our new partner, CIRM, in executing this clinical trial. The FDA clearance provides Asterias with imminent access to the previously announced $14.3 million CIRM grant, which provides non-dilutive funding to support both the clinical trial and other product development activities for AST-OPC1."
...that, will lay our final plans for associated marketing initiatives and strategies," said William Tew, Ph D , BioTime's Chief Commercial Officer. "HyStem-based products such as Premvia? and Renevia? (the latter anticipated to begin its pivotal clinical trial in Europe later this year) are anticipated to provide the company with opportunities for significant near-term revenue, while balancing the long-term opportunities created by the Company's pluripotent stem cell technology platform, which provides the potential for the industrial-scale manufacture of all of the cellular components of the human body. Together, these matrices and cellular building blocks provide a combination of technology platforms that we believe can lead the industry in the revolution underway commonly called 'regenerative medicine.'"

More Content

All (89) | News (49) | Reports (0) | Blogs (39) | Audio/Video (0) | Fact Sheets (1) | Press Releases (0)
sort by: Date | Relevance
Biogen Idec : Results Published from First Huma... [Published 4 Traders - 1 hour ago]
Change of Fate Commitment in Adult Neural Proge... [Published Journal of Neuroscience - 6 hours ago]
ERK1/2 Pathway-Mediated Differentiation of IGF-... [Published Plosone.org - 9 hours ago]
Stem cell trial for spinal cord injuries cleare... [Published Business First of Buffalo - 10 hours ago]
BioTime Unit Gets FDA Nod To Initiate Phase 1/2... [Published RTTNews.com - 15 hours ago]
Asterias receives clearance from FDA to initiat... [Published News-Medical.Net - 16 hours ago]
Principal Scientist: Immunoregulation [Published PharmaDiversity - Aug 27 2014]
MOG extracellular domain (p1-125) triggers elev... [Published Multiple Sclerosis Journal current issue - Aug 26 2014]
Hsp70 Regulates Immune Response in Experimental... [Published Plosone.org - Aug 25 2014]
Asterias Biotherapeutics Announces Investor Bri... [Published Bio-Medicine - Aug 25 2014]
8/25/14 - BioTime Receives FDA Premarket Notifi... [Published Pharmacy Choice - Aug 25 2014]
Stem Cell Therapies Hold Promise, But Obstacles... [Published Health Canal - Aug 22 2014]
Neuroantigen-Specific Autoregulatory CD8+ T Cel... [Published Plosone.org - Aug 21 2014]
A Prostate Cancer Drug maybe the answer to remy... [Published Multiple Sclerosis Research - Aug 21 2014]
Asterias Biotherapeutics Appoints Two Independe... [Published Wall Street Select - Aug 21 2014]
OPEXA THERAPEUTICS : Reports Second Quarter 201... [Published 4 Traders - Aug 20 2014]
Program-Specific Associate Professor Itaru Imay... [Published Noodls - Aug 20 2014]
Methods of generating mature oligodendrocytes [Published Free Patents Online - Aug 19 2014]
Saving oligodendrocytes [Published Multiple Sclerosis Research - Aug 19 2014]
Opexa Therapeutics Reports Second Quarter 2014 ... [Published Scottrade - Aug 14 2014]
Repair and regeneration of ocular tissue using ... [Published PharmCast - Aug 14 2014]
Agonists of neurotrophin receptors and their us... [Published PharmCast - Aug 14 2014]
Reports from Taipei Medical University Highligh... [Published HispanicBusiness.com - Aug 14 2014]
SYSTEM RESEARCH : Findings from Netherlands Can... [Published 4 Traders - Aug 13 2014]
Stem cell therapy for central nerve system inju... [Published EurekAlert! - Aug 13 2014]
The central role of mitochondria in axonal dege... [Published Multiple Sclerosis Journal RSS feed -- OnlineFi ... - Aug 13 2014]
Phosphatidic acid promotes remyelination [Published Multiple Sclerosis Research - Aug 12 2014]
Signalling Remyelination [Published Multiple Sclerosis Research - Aug 12 2014]
Stem Cells Grown From 86-Year-Old Man Morph int... [Published Alzheimer Research Forum - Aug 12 2014]
Deconvolving cell type expression patterns in G... [Published PNAS - Aug 12 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
MOG extracellular domain (p1-125) triggers elev... [Published Multiple Sclerosis Journal current issue - Aug 26 2014]
Background: Myelin-specific T cells are implicated in multiple sclerosis (MS) and drive experimental autoimmune encephalomyelitis (EAE). EAE is commonly induced with short peptides, whereas in MS, whole myelin proteins are available for immune response. ...
A Prostate Cancer Drug maybe the answer to remy... [Published Multiple Sclerosis Research - Aug 21 2014]
IRX4204, a retinoid X receptor-agonist studied for prostate cancer, also promotes differentiation of oligodendrocytes and the formation of regulatory T cells and inhibits the formation of TH 17 cells in vitro, suggesting its potential for myelin repair ...
Saving oligodendrocytes [Published Multiple Sclerosis Research - Aug 19 2014]
Vakilzadeh G, Khodagholi F, Ghadiri T, Darvishi M, Ghaemi A, Noorbakhsh F, Gorji A, Sharifzadeh M. Protective Effect of a cAMP Analogue on Behavioral Deficits and Neuropathological Changes in Cuprizone Model of Demyelination. Mol Neurobiol. 2014 Aug. ...
The central role of mitochondria in axonal dege... [Published Multiple Sclerosis Journal RSS feed -- OnlineFi ... - Aug 13 2014]
Neurodegeneration in multiple sclerosis (MS) is related to inflammation and demyelination. In acute MS lesions and experimental autoimmune encephalomyelitis focal immune attacks damage axons by injuring axonal mitochondria. In progressive MS, however, ...
Phosphatidic acid promotes remyelination [Published Multiple Sclerosis Research - Aug 12 2014]
Yamamoto S, Gotoh M, Kawamura Y, Yamashina K, Yagishita S, Awaji T, Tanaka M, Maruyama K, Murakami-Murofushi K, Yoshikawa K. Cyclic phosphatidic acid treatment suppress cuprizone-induced demyelination and motor dysfunction in mice. Eur J Pharmacol. 2014. ...
1 2 3 4 5 6 7 8
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.